Navigation Links
Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting
Date:5/1/2008

PHILADELPHIA May 1, 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.

Shire is committed to the advancement of ADHD research, and we are pleased to be presenting the efficacy and safety results from several studies of our ADHD treatments, said Gwendolyn Niebler, Vice President of Global Medical Affairs at Shire. We believe the physician community will find the lisdexamfetamine dimesylate, methylphenidate transdermal system and guanfacine extended release study findings to be presented at APA a relevant contribution to the growing body of research on our ADHD treatment options.

A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.

Lisdexamfetamine Dimesylate:
May 7, 2008; 12:00 p.m. ET
Lisdexamfetamine Dimesylate Treatment in Children Diagnosed with ADHD: Parental Impressions and Experiences
APA Poster Presentation # NR6-025

May 8, 2008; 11:00 a.m. ET
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults with ADHD
APA Oral Presentation Session # 28

Methylphenidate Transdermal System:
May 7, 2008; 12:00 p.m. ET
Long-Term Treatment Effects of the Methylphenidate Transdermal System in Boys and Girls with ADHD
APA Poster Presentation # NR6-018

Guanfacine Extended Release:
May 7, 2008; 12:00 p.m. ET
Guanfacine Extended Release: Duration of Effect in Children and Adolescents Aged 6 to 17 Years With ADHD
APA Poster Presentation # NR6-008

May 7, 2008; 12:00 p.m. ET
Response to Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With ADHD
APA Poster Presentation # NR6-040


'/>"/>

Contact: Lucia Lodato
212-601-8037
Porter Novelli
Source:Eurekalert

Related medicine news :

1. AUDIO from Medialink and Shire: What It Means to be an Adult With ADHD
2. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
3. VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda
4. New Hampshire AIDS Group Calls on Huckabee to Disavow His 1992 Statement
5. Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
6. New Hampshire: 1st in the Nation Primary State Takes a Stand on E-Prescribing
7. Families Invited to Celebrate Shire Day at Boston Childrens Museum
8. URAC CEO Testifies Before New Hampshire Legislators Regarding New URAC Standards for Pharmacy Benefit Management
9. Exciting New Plan from John Edwards on AIDS; Plan is Bold and Achievable, say New Hampshire Activists
10. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Ellevate Network, the leading network for professional women, brought together some of ... their inaugural Summit in New York City in June. The event was livestreamed with ... 3 million. To watch the Mobilize Women video, click here . , ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 West Pharmaceutical Services, Inc. ... injectable drug administration, today announced that it will release ... Thursday, October 26, 2017, and will follow with a ... at 9:00 a.m. Eastern Time. To participate on the ... conference ID is 94093362. ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology: